{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:10:42Z","timestamp":1781651442790,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.clinre.2021.101788","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T13:40:24Z","timestamp":1628602824000},"page":"101788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8085-4476","authenticated-orcid":false,"given":"Shaoming","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caining","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiankang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10272","key":"10.1016\/j.clinre.2021.101788_bib0001","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet North Am Ed"},{"issue":"6","key":"10.1016\/j.clinre.2021.101788_bib0002","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.clinre.2021.101788_bib0003","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/cncr.31942","article-title":"Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013","volume":"125","author":"Van Dyke","year":"2019","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clinre.2021.101788_bib0004","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00268-019-04966-4","article-title":"Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival","volume":"43","author":"Wu","year":"2019","journal-title":"World J Surg"},{"key":"10.1016\/j.clinre.2021.101788_bib0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.clinre.2021.101788_bib0006","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1245\/s10434-018-7075-4","article-title":"Actual 5-year survivors after surgical resection of hilar cholangiocarcinoma","volume":"26","author":"Tran","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clinre.2021.101788_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101936","article-title":"Current standards and future perspectives in adjuvant treatment for biliary tract cancers","volume":"84","author":"Lamarca","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinre.2021.101788_bib0008","unstructured":"NCCN clinical practice guidelines in oncology for hepatobiliary cancers[EB\/OL]. http:\/\/www.nccn.org."},{"key":"10.1016\/j.clinre.2021.101788_bib0009","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clinre.2021.101788_bib0010","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.hpb.2020.02.001","article-title":"Meta-analysis of randomized clinical trials of adjuvant chemotherapy for resected biliary tract cancers","volume":"22","author":"Ma","year":"2020","journal-title":"HPB (Oxford)"},{"issue":"12","key":"10.1016\/j.clinre.2021.101788_bib0011","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clinre.2021.101788_bib0012","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clinre.2021.101788_bib0013","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clinre.2021.101788_bib0014","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"issue":"7","key":"10.1016\/j.clinre.2021.101788_bib0015","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1245\/s10434-020-08355-3","article-title":"Phase 2 trial of adjuvant chemotherapy with S-1 for node-positive biliary tract cancer (N-SOG 09)","volume":"27","author":"Seita","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.clinre.2021.101788_bib0016","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/SLA.0000000000002865","article-title":"A prospective, randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer (KHBO 1208) kansai hepato-biliary oncology group","volume":"270","author":"Kobayashi","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.clinre.2021.101788_bib0017","unstructured":"Cochrane handbook for systematic reviews of interventions version 6.2, 2021[EB\/OL]. [2021]. https:\/\/training.cochrane.org\/handbook\/current."},{"key":"10.1016\/j.clinre.2021.101788_bib0018","first-page":"349","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","author":"Shamseer","year":"2015","journal-title":"BMJ-Br Med J"},{"key":"10.1016\/j.clinre.2021.101788_bib0019","series-title":"Research methods of evidence-based social science: Systematic review and meta-analysis","author":"Yang","year":"2018"},{"issue":"9","key":"10.1016\/j.clinre.2021.101788_bib0020","first-page":"1124","article-title":"Accessibility and validation of survival data in survival curve for meta-analysis","volume":"19","author":"Liu","year":"2019","journal-title":"Chinese Journal of Evidence-Based Medicine"},{"key":"10.1016\/j.clinre.2021.101788_bib0021","unstructured":"Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane, 2021.[EB\/OL]. www.training.cochrane.org\/handbook."},{"issue":"9","key":"10.1016\/j.clinre.2021.101788_bib0022","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"16","key":"10.1016\/j.clinre.2021.101788_bib0023","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clinre.2021.101788_bib0024","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/cncr.10831","article-title":"Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma","volume":"95","author":"Takada","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clinre.2021.101788_bib0025","doi-asserted-by":"crossref","first-page":"11770","DOI":"10.1038\/s41598-019-48099-z","article-title":"Benefit of adjuvant chemoradiotherapy in resected gallbladder carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.clinre.2021.101788_bib0026","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12094-017-1815-y","article-title":"Adjuvant concurrent chemoradiation therapy in patients with microscopic residual tumor after curative resection for extrahepatic cholangiocarcinoma","volume":"20","author":"Lee","year":"2018","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"10.1016\/j.clinre.2021.101788_bib0027","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00280-016-3014-x","article-title":"Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma","volume":"77","author":"Kim","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1016\/j.clinre.2021.101788_bib0028","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1111\/jgh.12321","article-title":"Adjuvant chemotherapy in resectable cholangiocarcinoma patients","volume":"28","author":"Wirasorn","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2021.101788_bib0029","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4174\/jkss.2012.83.4.227","article-title":"Prognostic factors for gallbladder cancer in the laparoscopy era","volume":"83","author":"Lee","year":"2012","journal-title":"J Korean Surg Soc"},{"key":"10.1016\/j.clinre.2021.101788_bib0030","first-page":"169","article-title":"Evaluation of postoperative adjuvant chemotherapy for intrahepatic cholangiocarcinoma patients undergoing R1 and R2 resections","volume":"13","author":"Bhudhisawasdi","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"10.1016\/j.clinre.2021.101788_bib0031","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijrobp.2008.10.052","article-title":"Adjuvant therapy for gallbladder carcinoma: the mayo clinic experience","volume":"75","author":"Gold","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clinre.2021.101788_bib0032","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2006.11.048","article-title":"Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct","volume":"68","author":"Hughes","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.clinre.2021.101788_bib0033","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1245\/s10434-018-6388-7","article-title":"Adjuvant therapy is associated with improved survival in resected perihilar cholangiocarcinoma: a propensity matched study","volume":"25","author":"Nassour","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.clinre.2021.101788_bib0034","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1245\/s10434-017-6139-1","article-title":"Adjuvant chemoradiotherapy is associated with improved survival for patients with resected gallbladder carcinoma: a systematic review and meta-analysis","volume":"25","author":"Kim","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clinre.2021.101788_bib0035","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/s12885-015-1617-y","article-title":"Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis","volume":"15","author":"Ma","year":"2015","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clinre.2021.101788_bib0036","doi-asserted-by":"crossref","first-page":"251","DOI":"10.21037\/hbsn.2018.03.14","article-title":"Effectiveness of additional resection of the invasive cancer-positive proximal bile duct margin in cases of hilar cholangiocarcinoma","volume":"7","author":"Ma","year":"2018","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"11","key":"10.1016\/j.clinre.2021.101788_bib0037","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1245\/s10434-008-9998-7","article-title":"Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone","volume":"15","author":"Borghero","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clinre.2021.101788_bib0038","doi-asserted-by":"crossref","first-page":"S1100","DOI":"10.1245\/s10434-015-4685-y","article-title":"Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: a multi-institutional experience","volume":"22","author":"Wang","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.clinre.2021.101788_bib0039","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ctrv.2011.05.003","article-title":"Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies","volume":"38","author":"Beltran","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.clinre.2021.101788_bib0040","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.semradonc.2018.06.003","article-title":"Radiotherapy for biliary tract cancers","volume":"28","author":"Keane","year":"2018","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"10.1016\/j.clinre.2021.101788_bib0041","doi-asserted-by":"crossref","DOI":"10.1186\/s12893-020-00718-7","article-title":"Intrahepatic cholangiocarcinoma - influence of resection margin and tumor distance to the liver capsule on survival","volume":"20","author":"Bartsch","year":"2020","journal-title":"BMC Surg"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740121001674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740121001674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:10Z","timestamp":1761895870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740121001674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2210740121001674"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2021.101788","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2021.101788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101788"}}